<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93970">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755455</url>
  </required_header>
  <id_info>
    <org_study_id>D11176</org_study_id>
    <secondary_id>CPHS#22884</secondary_id>
    <nct_id>NCT01755455</nct_id>
  </id_info>
  <brief_title>Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis</brief_title>
  <official_title>Iron Supplementation for the Hypoferremic Anemia of Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study questions whether low-dose ferrous sulfate taken by mouth daily for 6 weeks
      increases hemoglobin concentration in adult subjects with cystic fibrosis and hypoferremic
      anemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglobin concentration (gm/dl)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum iron (mcg/dl)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation (%)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hepcidin-25 (ng/ml)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum erythropoietin (mU/ml)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent-predicted forced expiratory volume in one second (FEV1%)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Akron Pulmonary Exacerbation Score (PES)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum iron (ng/mg)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Anemia, Iron-Deficiency</condition>
  <arm_group>
    <arm_group_label>Ferrous sulfate 325mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical-appearing tablet taken by mouth daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate 325mg</intervention_name>
    <description>Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks</description>
    <arm_group_label>Ferrous sulfate 325mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Pseudomonas aeruginosa colonization of the lung

          -  Transferrin saturation (TSAT) less than or equal to 21%

          -  Hemoglobin concentration &lt;15.5 gm/dl (men)

          -  Hemoglobin concentration &lt;13.6 gm/dl (women)

        Exclusion Criteria:

          -  Use of iron-containing vitamin or supplement

          -  Pregnancy

          -  Lactation

          -  Cirrhosis

          -  History of chronic visible (gross) hemoptysis

          -  Hereditary hemochromatosis

          -  History of transfusion-related iron overload

          -  Use of iron chelator(s)

          -  Withdrawal of informed consent

          -  Contraindication to phlebotomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex H Gifford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 21, 2012</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Alex H. Gifford</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Iron</keyword>
  <keyword>Hepcidin</keyword>
  <keyword>Anemia</keyword>
  <keyword>Erythropoiesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
